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Effects of Maternal Chemotherapy on Fetal and Childhood Development
Cancer is the name given to a collection of diseases characterized by abnormal cell
growth that can spread to other parts of the body. Under healthy circumstances, when cells
become old or damaged, they die. As a result, new cells are created to take their place.
However, as cancer develops, old and damaged cells survive when they are not supposed to
and new cells are created when they are not needed, forming tumors (National Cancer
Institute, 2015). These tumors can invade surrounding tissue and wreak havoc on the body.
Cancer diagnoses during pregnancy are uncommon. It is estimated that only 3,500 cases
are diagnosed each year, which correlates to approximately one case per 1,000 pregnancies
(0.1%) (Pavlidis, 2002). The management of cancer during pregnancy is complex since it
involves both the fetus and the mother. Although there are several treatment options
available, they are commonly aggressive and the effectiveness depends on the nature of the
patient and their specific diagnosis. The most aggressive treatment, chemotherapy, is often
used to kill cancer cells and shrink tumors, however, almost all drugs cross the placenta to
the fetus (Leslie, Koil, & Rayburn, 2005). Thus, outcomes after fetal exposure should be
examined.
The diagnosis of cancer during pregnancy can create dilemmas for patients and
health care providers. Pregnant women may be hesitant to receive cancer treatment due to
the potential effects it may have on their developing fetus. According to Doenges,
Moorhouse, and Murr (2016), decisional conflict may arise as a result of insufficient
information regarding healthcare options, uncertainty about the choices, or if the mother
recognizes that there may be undesirable consequences of the treatment being considered.
On the other hand, physicians may be hesitant to advise expecting mothers to discontinue

MATERNAL CHEMOTHERAPY ON DEVELOPMENT

3

their cancer treatment. Because patient autonomy is one of the most crucial aspects of
ethical nursing practice, it is important that pregnant women know the short and long-term
risks associated with receiving treatment during pregnancy (Dossey, Keegan, & Barrere,
2016). Examining the effects of chemotherapeutic agents, as well as other treatment
alternatives on fetal and childhood development is vital to enhancing maternal autonomy
and providing patient-centered care. Well-grounded studies uncovering the short and longterm outcomes of children born to mothers with a cancer diagnosis are limited. The
purpose of this thesis is to examine the effects of a maternal chemotherapy on fetal and
childhood development. Once identified, these effects will be organized into an educational
flier to help nurses better support expecting mothers and enhance their autonomy.
Literature Review
Optimal health does not solely mean the absence of disease, but refers to a state of
complete physical, emotional, and social well-being (WHO, 2020). Effectively coping with
stress, engaging in fulfilling relationships, and remaining free from disease are all key
aspects of a healthful life (CDC, 2020). The first section of this literature review examines
the effects of intrauterine chemotherapy exposure on later physical and cognitive
development of children. Next, the effects of a parental cancer diagnosis on childhood
behavior and mental health are explored. Finally, since breast cancer is commonly
diagnosed among women of childbearing age, studies that focus primarily on breast cancer
patients and their children are presented.
Physical and Cognitive Development
Chemotherapy targets rapidly growing cells, which is why the rapidly growing fetus
becomes a focal point for healthcare providers. Regardless of the type of diagnosis, the
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effects of cancer treatment on fetal development is a pronounced concern for women
diagnosed with cancer during pregnancy. Before conclusions can be made about the lasting
impact of chemotherapeutic agents on fetal development, extensive literature should be
explored.
In 2012, Amant, VanCalsteren et al. completed an observational follow-up study to a
multicenter cohort study that began in 2005. The follow-up study analyzed 70 children
who were prenatally exposed to maternal cancer staging and chemotherapy during the
second and third trimesters of pregnancy. Questionnaires regarding general health, school
performance, and behavioral and emotional problems were completed by parents. Several
neurological tests were performed to determine cognitive development and function of the
children. In addition, a detailed cardiac assessment consisting of a 12-lead
electrocardiograph (ECG) followed.
Among the 70 children exposed to chemotherapy in utero, 14 had a birth weight
below the tenth percentile (20%) (Amant, Van Calsteren et al., 2012). Babies who have a
birth weight below the tenth percentile for their gestational age are termed “small for
gestational age (SGA)” and may have higher odds of in-hospital death (Finken et al., 2018).
In 2011, 15 in every 1,000 term babies were considered SGA (1.5%) (Ewing et al., 2017). In
the study by Amant, Van Calsteren et al. (2012), babies exposed to chemotherapy in utero
had higher SGA rates than the general population in 2011. However, the incidence and type
of congenital malformations were similar to those of the general population and physical
examinations and echocardiographic assessments were within normal ranges. Two
children (one set of twins) had significant neurocognitive delays and were excluded from
further neurodevelopmental testing. Despite this, total IQ scores for the remaining children
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were within normal ranges and clinical examinations did not show any neurological
abnormalities (Amant, Van Calsteren et al., 2012). Behavior and general health also
corresponded with the results of the general population. Overall, fetal exposure to
chemotherapy was not specifically associated with poorer long-term outcomes in the
children in this study. It was concluded that the long-term outcomes of children in the
study were no different than those of the general population.
In 2012, Abdel-Hady et al. compared 61 chemotherapy-exposed children born
between 34-35 weeks with 60 non-exposed children born at the same gestational age.
Neonatal survival, birth weight, admission to a special care baby unit (SCBU), and
congenital malformations were evaluated. Overall, the findings suggested that there were
no statistically significant differences in neonatal survival, birth weight, SCBU admissions,
or congenital malformations. However, the control group did have better Apgar scores at 1minute and 5-minutes that were deemed statistically significant – the difference was not
significant after 10 minutes (Abdel-Hady, 2012).
Three years later, Cardonick et al. (2015) also investigated the relationship between
intrauterine chemotherapy exposure and cognitive ability, school performance, and
behavioral competence. In this study, a developmental psychologist performed
standardized testing on 35 children who were exposed to chemotherapy in utero and
compared the results to those of 22 children who were not exposed. In each of the three
areas, no significant differences were determined between the two groups. Across the
entire sample, 95% of children scored within the normal ranges on age-appropriate
cognitive assessments (Cardonick et al., 2015). When evaluating school performance,
mathematics and reading were included. Seventy one percent of all children in the study
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demonstrated adequate mathematic ability and 79% demonstrated adequate reading
ability (Cardonick et al., 2015). Behaviorally, eight children in the chemotherapy-exposed
group displayed behavior problems compared to four children in the non-exposed group
(Cardonick et al., 2015). However, these results were not significant. Like Amant et al.
(2012), Cardonick et al. (2015) found that no significant differences in cognitive ability,
school performance, and behavioral competence were noted in children who were exposed
to intrauterine chemotherapy.
The same year, Amant, Vandenbroucke et al. (2015) completed a similar casecontrol study and compared children whose mothers were diagnosed with cancer and
received chemotherapy during pregnancy with children whose mothers were not
diagnosed with cancer, and thus, did not receive chemotherapy. All chemotherapy was
administered after the first trimester of pregnancy. During the case-control study, health
questionnaires and medical files were used to collect data regarding general health.
Neurologic examinations and cognitive assessments were also performed. Cognitive
functioning was assessed using the Bayley Scales of Infant Development and cardiac
function was evaluated according to the American Society of Echocardiography (Amant,
Vandenbroucke et al., 2015).
Upon assessment, there were no significant differences in general health and
gestational age between the prenatal-exposure group and the control group. Children in
the prenatal-exposure group had an average gestational age of 36 weeks and the incidence
of medical problems that required surgery were similar between the two groups (Amant,
Vandenbroucke et al., 2015). Parental education, as well as sex, race, and country of origin
were considered covariates and were taken into consideration when evaluating cognitive
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development. Ultimately, results indicated that there were no significant differences in
cognitive outcome between children who were exposed to chemotherapy and children who
were not exposed. Overall, the cognitive outcomes were similar between groups. However,
in all children who were evaluated, there was an average increase of 2.9 points on the
Bayley Scales of Infant Development for each week of gestational age (Amant,
Vandenbroucke et al., 2015).
After analysis of cardiac function, it was discovered that there were no significant
differences in congenital malformations, heart rate, and blood pressure with the
chemotherapy-exposed group. Cardiac chamber size and wall thickness were within
normal measures, as well as ejection fraction, fractional shortening, longitudinal strain,
circumferential strain, and diastolic functioning (Amant, Vandenbroucke et al., 2015). In
conclusion, Amant, Vandenbroucke et al. (2015) found that prenatal chemotherapy
administered after the first trimester of pregnancy did not have clear adverse effects on
cognitive development or cardiac functioning in exposed children.
To further support the idea that chemotherapy does not have significant effects on
neonatal development, a systematic review completed by Esposito et al. (2016) explored
publications from the last 15 years related to cancer, chemotherapy, pregnancy, and
neonatal outcomes. The impact of chemotherapy on embryonic development, along with
the perinatal and long-term effects of chemotherapy administered during pregnancy on
children were investigated. Because organ formation mainly occurs during the first
trimester, the risks associated with the administration of cytotoxic drugs during that time
are much more pronounced. According to Gwyn (2005), the use of chemotherapy during
the first trimester has the greatest potential for harm to the fetus.
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Esposito et al. (2016) found that when chemotherapy is administered in the first
trimester, “the risk of malformations is approximately 7% to 17% when a single treatment
agent is used and increases to 25% in cases of combination therapy” (p. 2). These
malformations may specifically affect the heart, limbs, palate, neural tube, eyes, and ears.
However, the long-term impacts of intrauterine chemotherapy were evaluated and showed
significantly positive results. Subjects exposed to chemotherapy were followed throughout
high school and college and showed normal neurological and psychological development
(Esposito et al., 2016). The subjects displayed superior educational performance with no
learning disabilities (Esposito et al., 2016). In studies where cardiac functioning was
evaluated, there was no evidence of cardiac disease and no structural abnormalities were
detected (Esposito et al., 2016). In conclusion, Esposito et al. (2016) found that
chemotherapy administered during the first trimester is dangerous, however, when
administered during the second and third trimester, the risks of severe problems are low.
Behavior and Mental Health
Problems relating to physical health and cognition are a noticeable concern for
expecting mothers, however, a parental cancer diagnosis also has the potential to
significantly impact the psychosocial development of children. A cancer diagnosis can place
a considerable amount of stress on patients and their families, leading to impaired
parenting, less communication, and a lack of consistency in discipline (Faulkner & Davey,
2010). The physical and emotional demands of a cancer diagnosis may also make parents
physically and emotionally unavailable, which can cause children to experience
psychological stress. Because mental health is a crucial aspect of childhood development,
the topic should be explored further.
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By interviewing mothers and children who have been affected by a cancer diagnosis,
Hoke (2001) aimed to answer the following questions: Are children of mothers with breast
cancer more poorly adjusted when compared with children of mothers without breast
cancer? Are the medical characteristics of a mother’s diagnosis related to the child’s
outcomes? Do the mother’s psychological responses contribute to their child’s adjustment?
The study compared 28 mothers with breast cancer and their 35 children with 24 mothers
with benign biopsies and their 35 children. The Child Depression Inventory, the Revised
Children’s Manifest Anxiety Scale (RCMAS), The Youth Self-Report, and the Child Behavior
Checklist (CBCL) were used to assess affective response, behavior, and social functioning.
Both mothers and children participated in completing the assessment tools.
Upon analysis of the reported data, it was revealed that overall functioning did not
differ between children of mothers with a breast cancer diagnosis and children of mothers
with benign biopsies. Even though mothers with breast cancer reported more personal
psychological stress, both groups of children reported fewer anxiety symptoms than the
normative sample on the RCMAS scale (Hoke, 2001). Additionally, the Child Behavior
Checklist showed that mothers with breast cancer reported fewer behavior problems in
their children when compared with the normative sample (Hoke, 2001). Overall, this study
did not find evidence that children of breast cancer patients have increased adjustment
problems when compared to children of mothers without breast cancer.
Breast Cancer during Pregnancy
Occasionally, breast cancer occurs in women who are pregnant or recently
postpartum. According Visco, Meyer, Xi, & Brown (2009), breast cancer occurs
approximately once in every 3,000 pregnancies. As the childbearing age in the United
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States increases, the prevalence of breast cancer during pregnancy is also likely to increase.
Because breast cancer can be diagnosed during a woman’s childbearing years, it is
important to evaluate the significance of its treatment on pregnant women and their
unborn babies.
In 2006, Hahn et al. explained that the prognoses for women diagnosed with breast
cancer during pregnancy are similar to those of women without a cancer diagnosis. Even
though it has been shown that expecting mothers’ outcomes are favorable, concerns for
their unborn babies remain. Hahn et al. (2006) followed 57 pregnant women with invasive
breast cancer who gave written consent to receive treatment. The identity of each
diagnosis determined whether patients were eligible for surgical consultation, neoadjuvant
chemotherapy, or systemic chemotherapy (FAC). When evaluating the children who were
exposed to systemic chemotherapy in utero, gestational age at the beginning of treatment,
the number of cycles of FAC, and total dosages were recorded. To determine outcomes,
“neonatal complications, and subsequent health, development, and educational
performances” were obtained via parent and guardian surveys (Hahn et al., 2006, p. 1221).
At the time of the study, the children’s ages ranged from 2 to 157 months. In most cases,
chemotherapy was not initiated until the second trimester.
First and foremost, there were no stillbirths, miscarriages, or perinatal deaths
among children who were subjected to FAC chemotherapy in utero. Additionally, most of
the children did not have significant neonatal complications and primarily resembled the
general population (Hahn et al. 2006). When looking at school age children, only two
required special attention at school, one had attention deficit disorder, and one was
diagnosed with Down Syndrome (Hahn et al., 2006). All children, besides the child with
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Down Syndrome, were said to have normal development when compared with other
children at similar ages. Despite exposure to chemotherapy, all parents who responded to
the survey felt that their child was healthy. Another study conducted by Murthy et al.
(2014) presented similar findings.
Between 1992 and 2010, 81 pregnant women participated in an institutional review
board (IRB)-approved trial, in which they received a “standardized chemotherapy regimen
during the second and third trimesters of their pregnancy” and provided follow-up
information about their children (Murthy et al., 2014, p. 2). Prior to delivery, the patients
received combination chemotherapy. Each participant gave consent for their delivery
records to be obtained and health questionnaires were administered to collect data
regarding their child’s current health status and developmental/social history.
Out of the 81 participants, 63 participants or their next of kin answered the
questionnaire. Overall, 81 children were born after exposure to chemotherapy in utero at a
mean gestational age of 37 weeks and a mean birth weight of 2.9 kg (Murthy et al., 2014).
Twenty-eight of the children were delivered preterm, however, only two were delivered
before gestational week 33 and most of the preterm births were spontaneous without
complications. When evaluating neonatal complications among the sample, the following
complications were noted: required supplemental oxygen at the time of delivery (11), had
subarachnoid hemorrhage (1), had hypoglycemia (2), and had jaundice (3) (Murthy et al.,
2014). Of the children who had neonatal complications, 62% were exposed to more than
four cycles of chemotherapy in utero. Post-neonatal outcomes resembled the outcomes
presented in the study done by Hahn et al. (2006). Parents who responded to the survey
considered their children to be healthy overall. Twelve-percent of the survey responders
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reported developmental milestone delays, which included language delays (Murthy et al.,
2014). However, there were no significant cognitive abnormalities reported. Overall, “the
rate of congenital abnormalities in [the study’s] population [was] similar to the US average
rate” (Murthy et al., 2014, p. 5). Overall, it was found that combination chemotherapy
administered to patients during pregnancy does not impose significant health risks to fetal
development and the children in the study did not “indicate a higher rate of serious medical
problems than seen in the general population” (Murthy et al., 2014, p. 6).
The results of the breast cancer patients and their children were similar to the
results of patients with different types of cancer. However, it is important look at breast
cancer specifically since it is the most common form of cancer diagnosed during pregnancy
(Esposito et al., 2016).
Limitations
The goal of this literature review was to explore the effects of maternal
chemotherapy on fetal and childhood development and provide evidence to expecting
mothers to enhance their autonomy when determining courses of treatment. However,
limitations do exist within the review. One limitation is the age of the articles. Out of the 16
articles, most of them were written in the early 2000s and only five were written within the
last five years. The systematic review, written in 2016, is one of the most recent articles.
This indicates that the number of studies that explore the topic of maternal chemotherapy
on fetal and childhood development have decreased. It can be presumed that the
discontinuation of research was due to repetitive findings since the results of earlier
studies are comparable to the results of recent studies. This may show that throughout
time, the effects of maternal chemotherapy on fetal and childhood development has
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remained unchanged and does not pose significant risks. Sample size is another limitation
of this literature review. Many of the sample sizes in the studies were small. A small sample
size may reduce the power of the study and increase the margin of error.
When analyzing these findings, the presence of the blood-brain barrier should be
taken into consideration. According to Deeken and Löscher (2007), “the blood-brain
barrier is a physiologic obstruction to the delivery of systemic chemotherapy to the brain
parenchyma and central nervous system” (p. 1663). The reason there are limited cognitive
and developmental effects of chemotherapy on the developing fetus in these studies may
be due to the protective blood-brain barrier.
Implications for Practice and Conclusion
Pregnant patients who have been diagnosed with cancer have the right to decide
whether they will receive treatment during pregnancy or not. However, health-related
decisions should not be taken lightly, especially when the decisions can affect a mother and
her unborn baby. Expecting mothers may experience fear related to their diagnosis, which
can result in decisional conflict and impaired decision making. Thus, it is important to
determine the patient’s perception of the problem, actively listen to the patient’s concerns,
correct misperceptions the patient may have, and provide factual information (Doenges et
al., 2016). Helping the patient identify internal and external resources for assistance and
support may also enhance the client’s sense of optimism (Doenges et al., 2016).
Nurses and other health care providers have the knowledge and ability to encourage
patients to make well-informed decisions. Therefore, providing accurate data about the
short and long term effects of chemotherapy on fetal and childhood development is
essential. After exploring several studies, it has been repeatedly shown that maternal
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chemotherapy given after the first trimester of pregnancy does not appear to have a
significant impact on the physical or cognitive development of fetuses or children.
Maintaining open and transparent lines of communication gives health care providers the
opportunity to reassure patients that cancer treatment given after the first trimester is safe
for their unborn baby.
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The Nursing Crier
Effects of Maternal Chemotherapy on Fetal and Childhood
Development
Payton E. May

Western Michigan University Nursing Student

Scope and Impact of the Problem
It is estimated that nearly 3,500 women are
diagnosed with cancer during pregnancy each
year1,9. Although there are several treatment
options available, they can be aggressive.
Pregnant women may be hesitant to receive
cancer treatment due to the potential effects it
can have on their developing fetus. On the other
hand, physicians may be hesitant to advise
expecting mothers to discontinue their cancer
treatment. Because patient autonomy is one of
the most crucial aspects of ethical nursing
practice, it is important that pregnant women
know the short and long-term risks associated
with receiving chemotherapy during pregnancy.
Evaluating pediatric outcomes after
chemotherapy exposure and providing
expecting mothers with evidence-based
information are vital to enhancing patient
autonomy and providing quality patient care.

Expected Nursing Practice

Expecting mothers with a cancer diagnosis
should be provided evidence-based information
regarding the effects of cancer treatment on fetal
and childhood development to support their
decision to either undergo treatment during
pregnancy or withdraw.

Supporting Evidence

Patient-centered care and patient autonomy
are two of the most noteworthy aspects of
nursing practice. Allowing patients the
opportunity to analyze the short and long-term
effects of chemotherapy exposure will provide
them with a sense of control when deciding to
proceed with treatment or withdraw.

It is understandable that expecting mothers
may be hesitant to undergo treatment without
proper knowledge about its impact. However, it
is also understandable that health care
providers may be hesitant to guide patients to
discontinue treatment. One of the main goals of
quality health care is to provide the largest
benefit to the greatest number of individuals. By
providing adequate information, health care
providers can improve patient outcomes.
Studies have shown the following findings
regarding the effects of a maternal cancer
diagnosis and chemotherapy on fetal and
childhood development:
1. There are no significant differences in
cognitive ability when comparing children who
were exposed to chemotherapy in utero with
children who were not exposed6. Chemotherapy
is not associated with poorer
neurodevelopmental outcomes in children1,2,3,5,8.
Children exposed to chemotherapy scored
within normal ranges on age-appropriate
cognitive assessments2.
2. Congenital malformations, heart rate, and
blood pressure are similar between
chemotherapy-exposed children and children
who were not exposed3,7,8. Electrocardiograph
assessments and physical evaluations do not
show significant abnormalities in
chemotherapy-exposed chilren1,3. Overall
cardiac functioning is not impaired from
exposure to chemotherapy1,3,8.
3. No differences are noted in behavioral
competence between groups1,2,5. Parents also
report fewer behavior problems in
chemotherapy-exposed children4.
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4. Anxiety symptoms in chemotherapyexposed children are similar to those of nonexposed children4.
5. Exposed children who were followed
throughout high school and college showed
normal neurological and psychological
development8. The chemotherapy-exposed
children displayed superior educational
performance with no learning disabilities8.
6. Parents of children who have been
exposed to chemotherapy report that their
children maintain optimal levels of overall
health5,6. Overall, parent perceptions of child
wellness are positive.

Actions for Nursing Practice

Determine the patient’s perception of what is
occurring and how this will affect life. How the
client views the situation determines how they
will react10.
Actively listen to the client’s concerns.
Listening conveys a message of belief and
confidence in the client10.
Assist client in learning how to find factual
information. Knowledge gained will allow the
client to make well-informed decisions10.
Support involvement of family/significant
others as desired/appropriate. This will
provide the client with a local support system
and enhance familial relationships10.
Identify internal and external resources for
assistance. Helping the patient identify
available resources increases the likelihood
that they will be used in the future10.
Encourage contact with another individual
who has successfully dealt with a similar
fearful situation. This may enhance the client’s
sense of optimism10.

Need More Information or Help?

1. The National Cancer Institute offers
extensive up-to-date cancer information from
the United States government’s principle
agency for cancer research. This resource is
available at https://www.cancer.gov.
2. The National Foundation for Cancer
Research provides information regarding
research programs, tips to prevent and fight
cancer, and offers outlets to donate to cancer
research.
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To learn more, go to https://www.nfcr.org.
3. The Society for Maternal-Fetal Medicine
offers practice and career support, clinical
guidance, in-person and online educational
opportunities, patient safety recommendations,
and other supplemental documents to members.
This resource can be found at
https://www.smfm.org.
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